Catalyst Calendar

Wed, Sep 2, 2026

1 updates

7:00 AM

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA™ study; 100% (13/13) patients currently being tracked show complete donor chimerism Pauses further

Interim Data • Phase 1Interim data Wed, Sep 2, 2026tscan.com

Wed, Aug 12, 2026

1 updates

TCRX

7:00 AM

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass.,

Trial Start • Phase 3Trial initiation Wed, Aug 12, 2026tscan.com

Wed, Jul 29, 2026

1 updates

TCRX

7:00 AM

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

Actively enrolling patients across the US with anticipated topline data readout mid-2028 WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T)

Trial Start • Phase 3Trial initiation Wed, Jul 29, 2026tscan.com